Most Viewed Articles
Articles | Fulltext downloads | PDF downloads | Total downloads |
---|---|---|---|
Short CommunicationDriver mutations in oncogenesisFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_26_2020 |
35,385 | 3,994 | 39,379 |
Short CommunicationOutcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in BangladeshFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 1, January-April DOI: 10.25259/IJMIO_30_2020 |
30,146 | 3,080 | 33,226 |
Review ArticleMini review: Molecular pathology of personalized medicine in cancer susceptibility syndromesFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_12_2023 |
28,364 | 2,588 | 30,952 |
EditorialChallenging conventional wisdom in molecular oncology: New perspectivesFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_20_2023 |
26,857 | 2,445 | 29,302 |
Original ArticleOutcomes with atezolizumab and bevacizumab in hepatocellular carcinoma – Real-world data from IndiaFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_15_2023 |
26,670 | 2,461 | 29,131 |
Case ReportLong-term efficacy of osimertinib in de novo exon 19 deletion with T790M in an epidermal growth factor receptor mutated lung cancer patient in IndiaFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_16_2023 |
24,175 | 2,531 | 26,706 |
Review ArticleMolecular oncology and the role of artificial intelligence in advancing cancer treatmentFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_17_2023 |
22,784 | 1,837 | 24,621 |
EditorialCrucial crossroads: Making the right choice for first-line therapy in advanced urothelial cancerFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_2_2024 |
17,904 | 2,947 | 20,851 |
Review ArticleUse of five-day chronomodulated prescription of palbociclib as myelopreservation drug along with Topotecan in recurrent extensive stage small cell lung carcinoma – A perspective articleFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_3_2024 |
18,023 | 2,687 | 20,710 |
Original ArticleSpectrum of lymphomas in IndiaFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_18_2023 |
17,902 | 2,021 | 19,923 |
Review ArticleHigh-dose nicotinamide, a histone deacetylase inhibitor (Sirtuin-1), can prevent emergence of treatment resistance in chronic myeloid leukemia – A perspectiveFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_1_2024 |
16,661 | 2,420 | 19,081 |
NewsEditorial board tribute to Dr. Amit VermaFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December |
16,072 | 2,991 | 19,063 |
Review ArticleUnderstanding immunotherapy and CAR-T-cells: A narrative reviewFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_22_2023 |
16,695 | 2,199 | 18,894 |
Review ArticleCan CDK 4/6 inhibitors be used in patients with visceral crises? Deviating from conventional teachingFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_8_2022 |
13,677 | 5,076 | 18,753 |
Case ReportClinical experience of total body irradiation performed on Halcyon™ for a patient diagnosed with acute myeloid leukemiaFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_5_2022 |
12,781 | 5,801 | 18,582 |
Case ReportSquamous cell carcinoma of lung presenting as “Sunray sign” in chest radiographFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_6_2023 |
15,086 | 2,426 | 17,512 |
Cardio Oncology with ACOSIbrutinib and atrial fibrillation as cardiotoxicity – A new safety warning that impacts overall survivalFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_1_2022 |
12,404 | 4,473 | 16,877 |
Case ReportHyperthermic intraperitoneal chemotherapy in primary peritoneal cancer: Our experience in a young maleFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_16_2021 |
14,411 | 2,420 | 16,831 |
Review ArticleSignaling pathways in pancreatic ductile adenocarcinoma and potential therapeutic targetsFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_29_2022 |
14,402 | 2,330 | 16,732 |
New Drug UpdateAmlodipine-induced inhibition of NFAT-2 nuclear translocation and its utility as an additive to immune checkpoint inhibitorFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_13_2021 |
14,213 | 2,304 | 16,517 |
Review ArticleIs continuous infusion of high-dose ifosfamide, a safe option? Drug reviewFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 2, May-August DOI: 10.25259/IJMIO_21_2019 |
12,676 | 3,699 | 16,375 |
Review ArticleCombination of PARPi and anti-PD-L1 therapies in ovarian cancerFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 2, May-August DOI: 10.25259/IJMIO_28_2022 |
14,828 | 1,535 | 16,363 |
Review ArticlePotential therapeutic molecular targets for better outcomes for patients with lung cancerFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 2, May-August DOI: 10.25259/IJMIO_27_2022 |
15,078 | 1,176 | 16,254 |
Original ArticleIncorporation of immunohistochemistry in the assessment of survival and prognosis of endometrial cancers: Are we ready for the change?Full text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_2_2022 |
11,471 | 4,388 | 15,859 |
Review ArticleImmune dynamics of SARS-CoV-2 virus evolutionFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 1, January-April DOI: 10.25259/IJMIO_26_2021 |
11,004 | 4,732 | 15,736 |
Review ArticleAdvances in immunotherapy for metastatic esophageal cancerFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 3, September-December DOI: 10.25259/IJMIO_14_2022 |
10,858 | 4,537 | 15,395 |
Case SeriesDual driver in non-small cell lung carcinoma – therapeutic dilemmaFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 1, January-April DOI: 10.25259/IJMIO_22_2021 |
12,453 | 2,529 | 14,982 |
Review ArticleImmuno-oncological era of breast cancer: A progressive path to better treatmentFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_3_2022 |
9,434 | 5,414 | 14,848 |
Case ReportL1CAM expressing, ZFTA:: NCOA1 fusion-positive supratentorial ependymoma: A case reportFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_11_2023 |
12,920 | 1,727 | 14,647 |
Review ArticleThe evolving role of precision medicine in the management of advanced sarcomas – A mini reviewFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_6_2021 |
11,859 | 2,661 | 14,520 |
Review ArticleImmuno-oncology of differentiated thyroid cancerFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_36_2020 |
10,966 | 3,547 | 14,513 |
Brief CommentaryBreast cancer prognostic tools: A promising Indian optionFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 2, May-August DOI: 10.25259/IJMIO_15_2020 |
9,812 | 4,600 | 14,412 |
Review ArticlePost-chemotherapy maintenance treatment by nicotinamide riboside, a poly ADP ribose polymerase 1 inhibitor, in BRCA mutated advanced ovarian cancer – A perspectiveFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_12_2021 |
11,274 | 2,858 | 14,132 |
Review ArticleA compendium of population wide DNA methylation profile for oral cancer in IndiaFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_2_2021 |
10,280 | 3,785 | 14,065 |
Case ReportComplete metabolic response with letrozole and palbociclib in advanced breast cancerFull text![]() ![]() ![]() Year: 2019, Volume: 4, Issue: 3, September-December DOI: 10.25259/IJMIO_2_2019 |
8,782 | 5,155 | 13,937 |
Case ReportRedefining the treatment of metastatic uveal melanoma with immunotherapy – A case reportFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_11_2022 |
11,097 | 2,836 | 13,933 |
EditorialNanobytesFull text![]() ![]() ![]() Year: 2019, Volume: 4, Issue: 3, September-December DOI: 10.25259/IJMIO_7_2019 |
6,653 | 7,168 | 13,821 |
Review ArticleThe Cancer Genomic Atlas – “TO CONQUER CANCER”Full text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_28_2020 |
10,209 | 3,485 | 13,694 |
Case ReportUnusual presentation of an Epstein barr virus-negative extranodal natural killer/T cell lymphoma: A diagnostic dilemmaFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 1, January-April DOI: 10.25259/IJMIO_18_2021 |
11,292 | 2,365 | 13,657 |
Brief CommentaryERBB and FGFR2 pathway inhibition in biliary tract cancers – Dawn of a new beginningFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_10_2021 |
10,747 | 2,758 | 13,505 |
Conference Review6th Molecular Oncology Society Conference: Improving patient survival by molecularly targeted therapiesFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_20_2021 |
11,357 | 2,123 | 13,480 |
ErratumErratum for manuscript “Muir Torre Syndrome – An Indian Case report” (IJMIO_5_2020)Full text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, October DOI: 10.25259/IJMIO_05_2020_ER |
11,614 | 1,646 | 13,260 |
Review ArticleMolecular genetics changes in gallbladder carcinomaFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 2, May-August DOI: 10.25259/IJMIO_19_2019 |
8,979 | 4,229 | 13,208 |
Brief CommentaryBioactive lipid: A novel diagnostic approach for retinoblastoma in clinical managementFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_7_2021 |
10,307 | 2,776 | 13,083 |
Review ArticleResistance to poly ADP-ribose polymerase inhibitors and its clinical implicationsFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_12_2022 |
8,096 | 4,821 | 12,917 |
Review ArticleCell biological basis of tumor relapse and recurrence – A help from yeast quiescent biology and neuronal quiescent cell biologyFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 1, January-April DOI: 10.25259/IJMIO_18_2019 |
7,197 | 5,651 | 12,848 |
Letter to editorLetter to editorFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_10_2022 |
8,341 | 4,465 | 12,806 |
Review ArticleImpact of 2013 ASCO/CAP guidelines on various HER2 reporting categories in breast cancer by fluorescent in-situ hybridization and Immunohistochemistry: A meta-analysis with systematic reviewFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 1, January-April DOI: 10.25259/IJMIO_17_2019 |
6,585 | 6,129 | 12,714 |
Case ReportMetastatic endometrial carcinoma responsive to pembrolizumabFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 1, January-April DOI: 10.25259/IJMIO_18_2020 |
7,276 | 5,407 | 12,683 |
Review ArticleAntibody-drug conjugate review in breast cancer: A targeted approachFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 3, September-December DOI: 10.25259/IJMIO_30_2024 |
5,354 | 7,204 | 12,558 |